Feasibility of surgical orchiectomy in prostate cancer patients on long term luteinizing hormone-releasing hormone (LHRH) agonist therapy. Population-adjusted network meta-analyses (NMA) to evaluate ...

[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

2 “The impact of staging with PSMA PET on treatment decisions is not known,” they added in their poster. For their study, the investigators evaluated men with newly diagnosed prostate cancer at the ...

Use of the prostate-specific membrane antigen (PSMA) agent piflufolastat F 18 (18 F-DCFPyL PET/CT, Pylarify) in patients with biochemically recurrent prostate cancer was associated with a high ...

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.